Posted by admin on Aug 23rd, 2022 
Buckingham Strategic Wealth LLC lifted its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 3.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 72,579 shares of the company’s stock after purchasing an additional 2,260 shares during the period. Buckingham Strategic Wealth LLC’s holdings in Johnson & Johnson were worth $12,863,000 at the end of the most recent quarter.
Other large investors also recently modified their holdings of the company. Patron Partners LLC boosted its holdings in Johnson & Johnson by 12.7% in the 1st quarter. Patron Partners LLC now owns 6,625 shares of the company’s stock worth $1,174,000 after buying an additional 747 shares during the period. Palisade Capital Management LLC NJ boosted its holdings in Johnson & Johnson by 0.3% in the 1st quarter. Palisade Capital Management LLC NJ now owns 93,141 shares of the company’s stock worth $16,507,000 after buying an additional 250 shares during the period. Tandem Investment Advisors Inc. boosted its holdings in Johnson & Johnson by 4.8% in the 1st quarter. Tandem Investment Advisors Inc. now owns 326,505 shares of the company’s stock worth $57,867,000 after buying an additional 15,003 shares during the period. Argent Advisors Inc. boosted its holdings in Johnson & Johnson by 6.6% in the 1st quarter. Argent Advisors Inc. now owns 19,772 shares of the company’s stock worth $3,504,000 after buying an additional 1,218 shares during the period. Finally, Wealthsource Partners LLC boosted its holdings in Johnson & Johnson by 170.9% in the 1st quarter. Wealthsource Partners LLC now owns 49,055 shares of the company’s stock worth $8,694,000 after buying an additional 30,945 shares during the period. Hedge funds and other institutional investors own 68.78% of the company’s stock.
In related news, EVP Kathryn E. Wengel sold 40,000 shares of Johnson & Johnson stock in a transaction on Friday, June 10th. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the transaction, the executive vice president now owns 71,311 shares in the company, valued at approximately $12,336,803. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, CAO Robert J. Decker sold 8,462 shares of the business’s stock in a transaction dated Thursday, May 26th. The shares were sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the transaction, the chief accounting officer now owns 15,473 shares in the company, valued at $2,785,140. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Kathryn E. Wengel sold 40,000 shares of the business’s stock in a transaction dated Friday, June 10th. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the transaction, the executive vice president now owns 71,311 shares in the company, valued at approximately $12,336,803. The disclosure for this sale can be found here. 0.35% of the stock is owned by corporate insiders.
NYSE JNJ opened at $167.59 on Tuesday. Johnson & Johnson has a 52-week low of $155.72 and a 52-week high of $186.69. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.17 and a current ratio of 1.42. The company has a market capitalization of $440.62 billion, a P/E ratio of 24.39, a P/E/G ratio of 3.22 and a beta of 0.59. The company has a fifty day moving average of $173.36 and a 200-day moving average of $174.54.
Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.57 by $0.02. The company had revenue of $24.02 billion during the quarter, compared to the consensus estimate of $23.85 billion. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.14%. The firm’s revenue was up 3.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.48 EPS. As a group, equities research analysts predict that Johnson & Johnson will post 10.05 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd will be given a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a yield of 2.70%. The ex-dividend date of this dividend is Monday, August 22nd. Johnson & Johnson’s payout ratio is presently 65.79%.
Several research analysts recently commented on the stock. UBS Group cut their price objective on shares of Johnson & Johnson from $185.00 to $180.00 in a report on Thursday, July 21st. Citigroup cut their price target on shares of Johnson & Johnson from $205.00 to $201.00 in a report on Wednesday, July 20th. Daiwa Capital Markets started coverage on shares of Johnson & Johnson in a report on Wednesday, June 22nd. They issued an “outperform” rating for the company. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, May 17th. Finally, Wells Fargo & Company raised their price target on shares of Johnson & Johnson from $190.00 to $195.00 and gave the company an “overweight” rating in a report on Wednesday, July 13th. Four equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $189.89.
(Get Rating)
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.
Huntington National Bank Purchases 507 Shares of Devon Energy Co. (NYSE:DVN)
Advanced Research Investment Solutions LLC Boosts Stock Holdings in Johnson & Johnson (NYSE:JNJ)
About Author
